Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)
Completed · Phase 3
Conditions studied: Hypoparathyroidism
In brief
Use of PTH (1-84) a recombinant hormone in 25 µg or 50 µg doses for the treatment of adults with hypoparathyroidism. The use of PTH (1-84) should result in a decrease of calcium and vitamin D supplements.
Key facts
- Study ID
- NCT01268098
- Run by
- Shire
- People needed
- 42
- Starts
- 2011-02-09
- Expected to finish
- 2011-11-11
- Last updated by the study team
- 2021-06-11
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Advance Medical Research LLC — Lakewood, California, United States
- University of Chicago Medical Center — Chicago, Illinois, United States
- Indiana University School of Medicine — Indianapolis, Indiana, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Michigan Bone & Mineral Clinic PC — Detroit, Michigan, United States
- Mayo Clinic Rochester — Rochester, Minnesota, United States
- Columbia University Medical Center — New York, New York, United States
- University Physicians Group — Staten Island, New York, United States
- Physician East PA — Greenville, North Carolina, United States
- University of Cincinnati Bone Health and Osteoporosis Center — Cincinnati, Ohio, United States
- Cetero Research DGD Research Inc. — San Antonio, Texas, United States
- The Vancouver Clinic — Vancouver, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.